By Counterforce Health Team in Orfadin (nitisinone) —

How to Get Orfadin (nitisinone) Covered by Cigna in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Orfadin (nitisinone) Covered by Cigna in California

Cigna requires prior authorization for Orfadin (nitisinone) with confirmed hereditary tyrosinemia type 1 diagnosis, metabolic specialist involvement, and dietary restriction plan. In California, if denied, you can appeal internally (30 days) then request Independent Medical Review through DMHC with 55%+ overturn rates for medical necessity denials.

First steps today: 1) Gather HT-1 lab results (succinylacetone levels) and genetic testing, 2) Request specialist consultation if needed, 3) Document tyrosine-restricted diet plan with dietitian.

Table of Contents

Coverage Requirements at a Glance

Requirement What It Means Documentation Needed Source
Prior Authorization Required for all Orfadin prescriptions PA form via Cigna portal Cigna PA Policy
HT-1 Diagnosis Confirmed hereditary tyrosinemia type 1 Elevated succinylacetone, genetic testing Cigna Nitisinone Policy
Specialist Involvement Metabolic disease specialist prescription/consultation Specialist notes, referral documentation Cigna Nitisinone Policy
Dietary Management Tyrosine/phenylalanine restricted diet Dietitian assessment, meal plan Cigna Nitisinone Policy
No Duplication Not used with other nitisinone products Medication history review Cigna Nitisinone Policy

Step-by-Step: Fastest Path to Approval

1. Confirm HT-1 Diagnosis (1-2 days)

Who: Your doctor orders tests
What: Blood succinylacetone levels, genetic testing (FAH gene), liver function tests
Timeline: Lab results within 24-48 hours for urgent cases
Source: HRSA Newborn Screening

2. Get Specialist Consultation (3-7 days)

Who: Primary care refers to metabolic specialist
What: Specialist evaluation, treatment plan documentation
Timeline: Urgent referrals processed within 3-5 business days
Portal: Submit via Cigna Provider Portal

3. Establish Dietary Plan (1-2 days)

Who: Registered dietitian assessment
What: Tyrosine restriction (<20-30 mg/kg/day), meal planning
Timeline: Same-day consultation possible for urgent cases
Note: Essential for Cigna approval criteria

4. Submit Prior Authorization (Same day)

Who: Prescribing physician
What: Complete PA form with all supporting documents
How: Cigna Provider Portal or call 1-800-882-4462
Timeline: 5-7 business days standard, 24-72 hours expedited

5. Specialty Pharmacy Setup (1-2 days post-approval)

Who: Cigna coordinates with Express Scripts/Accredo
What: Specialty drug dispensing and monitoring
Timeline: First shipment within 24-48 hours of approval

Common Denial Reasons & How to Fix Them

Denial Reason Fix Strategy Required Documentation
"No confirmed HT-1 diagnosis" Submit biochemical and genetic evidence Succinylacetone >1 mmol/L, FAH gene mutations
"Lack of specialist involvement" Get metabolic specialist consultation Consultation notes, referral documentation
"Missing dietary plan" Provide registered dietitian assessment Tyrosine restriction plan, compliance monitoring
"Step therapy required" Document contraindications or failures Previous medication trials, adverse reactions
"Quantity limits exceeded" Submit dosing rationale Weight-based calculations, specialist recommendations
From Our Advocates: We've seen many HT-1 families initially denied because their pediatrician submitted the PA without specialist involvement. Getting that metabolic specialist consultation upfront—even just a brief review of the case—dramatically improves approval odds and prevents weeks of back-and-forth appeals.

Medical Necessity Letter Template

Use this template for appeals or peer-to-peer reviews:

Patient: [Name], DOB: [Date], Member ID: [ID]
Diagnosis: Hereditary tyrosinemia type 1 (ICD-10: E70.21)
Requested Medication: Orfadin (nitisinone) [dose] mg capsules

Clinical Summary:
[Age]-year-old patient with confirmed HT-1 diagnosed [date]. Biochemical confirmation via succinylacetone elevation to [value] mmol/L (normal <1). Genetic testing revealed [specific FAH mutations if available].

Medical Necessity Rationale:

  • FDA-approved indication for HT-1 as adjunct to dietary restriction
  • Only available treatment to prevent liver failure and hepatocellular carcinoma
  • Patient on tyrosine-restricted diet (<30 mg/kg/day) per registered dietitian
  • Prescribed by metabolic specialist [name] on [date]

Monitoring Plan:

  • Succinylacetone levels every 1-3 months (target <1 mmol/L)
  • Liver function tests quarterly
  • Ophthalmologic exams for corneal monitoring
  • Dietary compliance assessment with registered dietitian

Supporting Evidence:

  • FDA prescribing information
  • Metabolic specialist consultation notes
  • Laboratory results confirming HT-1 diagnosis
  • Registered dietitian assessment and meal plan

California Appeals Process

Internal Appeal (First Level)

Timeline: File within 180 days of denial
Process: Submit via Cigna member portal or mail
Decision: 30 days standard, 72 hours expedited
Required: Appeal form, medical records, denial letter

Independent Medical Review (External Appeal)

Eligibility: After internal appeal denial or 30-day non-response
Timeline: File within 6 months via DMHC portal
Decision: 45 days standard, 7 days expedited
Cost: Free to patients
Success Rate: 55%+ for medical necessity denials (DMHC data)

Note: California's Independent Medical Review has particularly high success rates for rare disease medications when proper documentation is provided.

Peer-to-Peer Review Scripts

Requesting the Call

"I'm Dr. [Name] requesting a peer-to-peer review for [Patient Name], member ID [ID], regarding the Orfadin denial. The patient has confirmed hereditary tyrosinemia type 1, and I have additional clinical information that supports medical necessity. Can we schedule within 24 hours given the urgency?"

Key Talking Points

  • Confirmed diagnosis: "Succinylacetone elevated to [value], genetic testing shows FAH mutations"
  • Specialist involvement: "Prescribed by metabolic specialist Dr. [Name] at [Institution]"
  • Dietary compliance: "Patient on strict tyrosine restriction per registered dietitian"
  • Medical necessity: "Only FDA-approved treatment for HT-1; prevents liver failure"
  • Monitoring plan: "Regular succinylacetone monitoring, target <1 mmol/L"

When External Review Makes Sense

Consider California's Independent Medical Review when:

  • Internal appeal denied despite strong clinical evidence
  • Urgent clinical need (expedited IMR available)
  • Denial based on "experimental/investigational" determination
  • Step therapy requirements inappropriate for rare disease

How to Request IMR:

  1. Complete DMHC IMR application
  2. Attach internal appeal denial letter
  3. Include all clinical documentation
  4. Submit within 6 months of internal denial

Contact DMHC Help Center: 888-466-2219 for assistance

Cost Savings Options

Manufacturer Support

  • Orfadin4U Program: Potential $0 copay for eligible patients
  • Contact: Check eligibility at manufacturer website or call patient support

Foundation Assistance

  • National Organization for Rare Disorders (NORD): Medication assistance programs
  • HealthWell Foundation: Copay assistance for rare diseases

State Programs

  • Medi-Cal: California Medicaid coverage for eligible patients
  • Covered California: Marketplace plans with essential health benefits

Counterforce Health helps patients and clinicians navigate complex prior authorization and appeals processes by creating evidence-based appeals that align with payer policies. Their platform analyzes denial letters and generates targeted rebuttals using the right clinical evidence and procedural requirements.

FAQ

Q: How long does Cigna prior authorization take for Orfadin?
A: Standard PA decisions within 5-7 business days; expedited reviews in 24-72 hours for urgent cases. Submit complete documentation to avoid delays.

Q: What if Orfadin is not on Cigna's formulary?
A: Request formulary exception with medical necessity documentation. Cigna formulary exception process requires prescriber submission with clinical rationale.

Q: Can I get expedited appeals in California?
A: Yes, both Cigna internal appeals and DMHC Independent Medical Review offer expedited processes for urgent clinical situations (72 hours and 7 days respectively).

Q: Does step therapy apply to Orfadin for HT-1?
A: Generally no, as Orfadin is the only FDA-approved treatment for HT-1. However, some plans may require trial of generic nitisinone first.

Q: What happens if my IMR is denied?
A: IMR decisions are binding on health plans. If denied, consider working with Counterforce Health to explore alternative approaches or formulary alternatives.

Q: How often do I need to renew Orfadin authorization?
A: Typically every 6-12 months with updated laboratory results (succinylacetone levels) and specialist assessment demonstrating ongoing benefit.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and clinical circumstances. Always consult your healthcare provider and insurance plan documents for specific guidance. For assistance with complex appeals, consider consulting with specialized advocacy services like Counterforce Health.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.